Stockscreener 앱 받기
2.57
0.00%
0.00
시간 외 거래:
2.57
Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia - GlobeNewswire
Esperion's Cholesterol Drug Shows 25% LDL Reduction in Japan Trial, Advances to NDA | ESPR Stock News - StockTitan
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Esperion to Present at Piper Sandler Healthcare Conference, Showcases Cardiovascular Pipeline | ESPR Stock News - StockTitan
Esperion's chief commercial officer sells shares worth $426 By Investing.com - Investing.com South Africa
Esperion's chief commercial officer sells shares worth $426 - Investing.com
Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright - MarketBeat
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 - The Manila Times
Esperion Highlights New Exploratory Data from CLEAR - GlobeNewswire
Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com - MarketBeat
ESPR: 3 Growth Stocks Under $10 That Analysts Predict Will Skyrocket - StockNews.com
Two Seas Capital LP Acquires Significant Stake in Esperion Thera - GuruFocus.com
Esperion Therapeutics: Growth Initiatives Are Paying OffBuy - Seeking Alpha
Esperion Therapeutics Q3 2024 Earnings Preview - MSN
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates - MSN
What is HC Wainwright's Estimate for ESPR FY2025 Earnings? - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call Transcript - Insider Monkey
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... By GuruFocus - Investing.com Canada
Esperion Therapeutics: Q3 Earnings Snapshot - Darien Times
Esperion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y - Yahoo Finance
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update - The Manila Times
Esperion Q3 Revenue Surges 52% to $51.6M as Prescription Growth Accelerates | ESPR Stock News - StockTitan
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Buy" - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Esperion Therapeutics Inc - GuruFocus.com
Esperion to Participate in Upcoming Jefferies London Healthcare Conference - GlobeNewswire
Esperion Announces a Featured Presentation in the Late - GlobeNewswire
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three - The Bakersfield Californian
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions - Yahoo Finance
Esperion Therapeutics (ESPR) Set to Announce Quarterly Earnings on Thursday - MarketBeat
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy - MarketBeat
Esperion to Report Third Quarter 2024 Financial Results on November 7 - GlobeNewswire
ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Nexletol From Esperion - Pharmacy Times
Esperion Therapeutics' chief commercial officer sells shares worth $226 - Investing.com
Esperion Therapeutics' chief commercial officer sells shares worth $226 By Investing.com - Investing.com UK
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Yahoo Finance
INVA: 3 Small-Cap Biotech Stocks With Game-Changing Potential - StockNews.com
Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by Zacks Research - MarketBeat
Zacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR) - MarketBeat
1.57%
1.69%
자본화:
|
볼륨(24시간):